Drug intelligence / Profile preview

KINE-501A

Development stage: Preclinical
Lead developer: Kine Sciences
Modality: Peptides

Overview

KINE-501A is a **peptide** drug candidate from **Kine Sciences** being developed for **Alzheimer's disease**. In the company's pipeline, it is described as targeting **microglial cells**, suggesting an immunomodulatory approach intended to modify neuroinflammatory or neurodegenerative processes relevant to Alzheimer's disease. Publicly available pipeline information indicates that the program is at the **discovery** stage, and no more specific molecular target, formulation, route of administration, or clinical data were disclosed in the provided source.

Beyond the preview

Go deeper on KINE-501A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KINE-501A.

Explore the full profile